1216 - BIOLOGICAL FEATURES of B-CLL AND RESIDUAL IMMUNITY AT TREATMENT INITIATION DETERMINE IMMUNITY ON BTKI THERAPY.

Co-Author(s)

MH

Marie Hodges, PhD

University of Birmingham
Birmingham, England, United Kingdom
JD

Jared Darcy, MRes

University of Birmingham
Birmingham, England, United Kingdom
RB

Rachel Bruton, PhD

University of Birmingham
Birmingham, England, United Kingdom
TR

Thomas Roberts, MSc

University of Oxford
Oxford, England, United Kingdom
WC

Wayne Croft, PhD

University of Birmingham
Birmingham, England, United Kingdom
PM

Paul Moss, PhD

Professor of Haematology
University of Birmingham
Birmingham, England, United Kingdom
MP

Matt Pugh, PhD

University of Birmingham
Birmingham, England, United Kingdom
JC

Jonathan Cook, PhD

University of Oxford
Oxford, England, United Kingdom
GP

Guy Pratt, PhD

University of Birmingham
Birmingham, England, United Kingdom
NK

Naeem Khan, PhD

University of Birmingham
Birmingham, England, United Kingdom
BW

Brian Willett, PhD

University of Glasgow
Glasgow, Scotland, United Kingdom
Piers Patten, BSc, MBChB, PhD

Clinical Senior Lecturer, Consultant Haematologist
King's College London
London, England, United Kingdom
Talha Munir, MBBS, MRCP, FRCPath, PhD

Consultant Haematologist
Leeds Teaching Hospitals NHS Trust
Leeds, England, United Kingdom
AR

Andy Rawstron, PhD

Leeds Teaching Hospitals NHS Trust
Leeds, England, United Kingdom
MN

Mohammed Nimir, MBChB

University of Birmingham
Birmingham, England, United Kingdom